Shingles Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's "Shingles Pipeline Insight 2026" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Shingles pipeline landscape. It covers the Shingles pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Shingles pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Shingles Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/shingles-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Shingles Pipeline Report
• In August 2026, the U.S. FDA approved a prefilled syringe presentation of GSK's Shingrix vaccine, providing a ready-to-use formulation that eliminates the need to reconstitute separate vaccine vials and may simplify administration for healthcare professionals.
• In July 2026, GSK Canada announced approval of a prefilled syringe presentation of Shingrix, expanding access to a more convenient administration format for the prevention of herpes zoster and its complications.
• DelveInsight's Shingles Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Shingles treatment.
• The leading Shingles Companies such as Zhuhai Trinomab Pharmaceutical, Nobelpharma, Dynavax Technologies Corporation, Jiangsu Rec-Biotechnology, Moderna, Curevo, Amytrx Therapeutics, and others.
• Promising Shingles Therapies such as Zoster Vaccine Live, Valacyclovir, FV-100, JCXH-105, GSK 1437173A, Z-1018, EPB-348 and others.

Want to know which companies are leading innovation in Shingles? Dive into the full pipeline insights @ https://www.delveinsight.com/sample-request/shingles-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Shingles Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Shingles Pipeline Report also highlights the unmet needs with respect to the Shingles.

Shingles Overview
Shingles, also known as herpes zoster, is a viral disease caused by the reactivation of the varicella-zoster virus, which remains dormant in the sensory ganglia after an initial chickenpox infection. Typically affecting adults and the elderly, shingles arises when the immune system can no longer keep the virus in check. The incidence of shingles is strongly correlated with immune status, with those maintaining robust immunity rarely developing the condition. Shingles is not merely a benign infection; it can present in various forms and often leads to complications such as postherpetic neuralgia, a persistent and severe pain that continues even after the rash has resolved. Understanding and managing shingles is crucial, especially for those with weakened immune systems, to mitigate its impact and complications.

Shingles Emerging Drugs Profile
• Amezosvatein: Curevo Vaccine
Amezosvatein (CRV-101) is an investigational non-mRNA adjuvanted sub-unit vaccine for the prevention of shingles (herpes zoster in adults and chickenpox (varicella) in children. As a sub-unit vaccine, amezosvatein does not contain virus components and cannot cause infection. Amezosvatein targets glycoprotein E (gE) on the varicella virus, a target proven by others to be safe and effective for the prevention of shingles. The adjuvant component of amezosvatein was specifically engineered with the intent of producing an optimal immune response while improving tolerability. Currently, the drug is in Phase II stage of its clinical trial for the treatment of shingles.

• REC610: Jiangsu Recbio Technology
REC610, a novel adjuvanted recombinant shingles vaccine developed by Jiangsu Recbio Technology, received a clinical trial approval notice from the National Medical Products Administration (NMPA) in October 2023. The vaccine demonstrated a positive safety profile in a phase I trial in the Philippines, where it was compared to GSK's Shingrix. REC610 showed a favorable safety and tolerability profile in healthy participants aged 40 and above after two doses of vaccination, with no serious adverse events reported. The vaccine induced strong gE-specific humoral and cellular immune responses, which peaked at 30 days after the second vaccination. Currently, the drug is in Phase I stage of its clinical trial for the treatment of shingles.

If you're tracking ongoing Shingles Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ https://www.delveinsight.com/sample-request/shingles-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Shingles Companies
Zhuhai Trinomab Pharmaceutical, Nobelpharma, Dynavax Technologies Corporation, Jiangsu Rec-Biotechnology, Moderna, Curevo, Amytrx Therapeutics, and others.

The Shingles Pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Shingles with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Shingles Treatment.
• Shingles Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Shingles Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Shingles market.

Shingles pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Shingles Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Shingles Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Shingles Pipeline Report covers it all - check it out now @ https://www.delveinsight.com/sample-request/shingles-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Shingles Pipeline Report
• Coverage- Global
• Shingles Companies- Zhuhai Trinomab Pharmaceutical, Nobelpharma, Dynavax Technologies Corporation, Jiangsu Rec-Biotechnology, Moderna, Curevo, Amytrx Therapeutics, and others.
• Shingles Therapies- Zoster Vaccine Live, Valacyclovir, FV-100, JCXH-105, GSK 1437173A, Z-1018, EPB-348 and others.
• Shingles Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Shingles Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Shingles Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/shingles-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Introduction
2. Executive Summary
3. Shingles: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Shingles- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Amezosvatein: Curevo Vaccine
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. REC610: Jiangsu Recbio Technology
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug profiles in the detailed report.....
18. Inactive Products
19. Shingles Key Companies
20. Shingles Key Products
21. Shingles- Unmet Needs
22. Shingles- Market Drivers and Barriers
23. Shingles- Future Perspectives and Conclusion
24. Shingles Analyst Views
25. Shingles Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.